Fyarro
Total Payments
$15.8M
Transactions
896
Doctors
502
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $15.4M | 355 | 229 |
| 2023 | $393,912 | 541 | 329 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.4M | 50 | 97.4% |
| Consulting Fee | $193,806 | 53 | 1.2% |
| Honoraria | $130,270 | 50 | 0.8% |
| Food and Beverage | $40,478 | 668 | 0.3% |
| Travel and Lodging | $16,373 | 36 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,755 | 6 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $8,000 | 2 | 0.1% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research
$15.4M
50 transactions
General
$403,707
846 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | Aadi Bioscience, Inc. | $7.0M | 0 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Aadi Bioscience, Inc. | $5.5M | 0 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Aadi Bioscience, Inc. | $2.5M | 0 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | Aadi Bioscience, Inc. | $180,605 | 0 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | Aadi Bioscience, Inc. | $75,252 | 0 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | Aadi Bioscience, Inc. | $52,676 | 0 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Aadi Bioscience, Inc. | $38,440 | 0 |
Top Doctors Receiving Payments for Fyarro
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $15.4M | 52 |
| , M.D | General Practice | San Francisco, CA | $78,000 | 4 |
| , MD | Medical Oncology | Boston, MA | $47,475 | 8 |
| , M.D | Medical Oncology | Beverly Hills, CA | $39,634 | 53 |
| , M.D | Hematology & Oncology | Santa Monica, CA | $24,712 | 12 |
| , M.D | Gynecologic Oncology | Cincinnati, OH | $23,653 | 10 |
| , MD | Medical Oncology | New York, NY | $8,997 | 5 |
| , MD | Pediatric Hematology-Oncology | Santa Monica, CA | $8,713 | 9 |
| , MD | Gynecologic Oncology | West Palm Beach, FL | $7,040 | 5 |
| , M.D | Hematology & Oncology | Boston, MA | $6,476 | 4 |
| , APRN | Family | Miami, FL | $5,363 | 9 |
| , MD | Obstetrics & Gynecology | Oklahoma City, OK | $5,320 | 4 |
| , MD | Surgery | Newport Beach, CA | $5,239 | 3 |
| , M.D | Gynecologic Oncology | Fort Lauderdale, FL | $4,470 | 4 |
| , M.D | Gynecologic Oncology | Orange, CA | $3,966 | 3 |
| , MD, PHD | Medical Oncology | Seattle, WA | $3,946 | 7 |
| , M.D | Hematology & Oncology | Pittsboro, NC | $3,670 | 3 |
| , MD | Medical Oncology | Cleveland, OH | $3,655 | 2 |
| , M.D | Gynecologic Oncology | Houston, TX | $3,500 | 1 |
| , MD | Medical Oncology | Englewood, NJ | $3,500 | 1 |
| , MD | Medical Oncology | Dallas, TX | $3,500 | 1 |
| , MD | Internal Medicine | Aurora, CO | $3,270 | 3 |
| , M.D | Internal Medicine | New York, NY | $3,215 | 2 |
| , MD | Gynecologic Oncology | Saint Louis, MO | $3,106 | 2 |
| , M.D., PH.D | Medical Oncology | Columbus, OH | $3,106 | 2 |
Ad
Manufacturing Companies
- Aadi Bioscience, Inc. $15.8M
Product Information
- Type Drug
- Total Payments $15.8M
- Total Doctors 502
- Transactions 896
About Fyarro
Fyarro is a drug associated with $15.8M in payments to 502 healthcare providers, recorded across 896 transactions in the CMS Open Payments database. The primary manufacturer is Aadi Bioscience, Inc..
Payment data is available from 2023 to 2024. In 2024, $15.4M was paid across 355 transactions to 229 doctors.
The most common payment nature for Fyarro is "Unspecified" ($15.4M, 97.4% of total).
Fyarro is associated with 7 research studies, including "Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1" ($7.0M).